GLP-1 receptor agonists — Ozempic, Wegovy, and their competitors — have been the biggest story in consumer health for three years. Their sexual health effects are only now getting systematic attention. On April 16, 2026, SELF reported on Kinsey Institute research finding that GLP-1 drugs are changing sex and dating for 50–60% of users, with men twice as likely as women to report increased libido. Earlier that month, a Medscape review published April 7 examined the nuanced effects on women specifically, including vaginal dryness attributable not to the drugs directly but to the rapid weight loss and associated dehydration they produce.

Why It Matters

When 50% of GLP-1 users report that the drugs are changing their sex lives, a 50-million-and-growing user cohort is describing a massive intersection between the pharmaceutical category and the sexual wellness market. The research is still nascent, but the directional signals are clear: GLP-1 drugs are a sexual wellness story, and the brands positioned at the intersection will be building real competitive moats.

The Kinsey Institute research, led by Dr. Justin Lehmiller, found that the libido and sexual confidence changes GLP-1 users report are not merely cosmetic body-image effects. Users describe changes in sexual desire, partner attraction, and dating behavior that go beyond feeling better about their appearance — suggesting the medications may have physiological effects on sexual function independent of weight loss. The gender asymmetry is notable: men's sexual health benefits appear more consistent and pronounced, while women's experience is more variable and includes the vaginal dryness side effect that may require additional sexual wellness intervention.

The practical implications cross multiple sex tech and sexual wellness categories. For femtech companies addressing vaginal dryness (lubricant brands, pelvic health platforms, menopause tech), GLP-1's widespread adoption creates a new addressable population of users experiencing dryness who are not perimenopausal and may not self-identify as needing vaginal health products. For male sexual health platforms like Hims, Ro, and Roman, the GLP-1 libido correlation creates potential upselling context — users already managing their health through telehealth may be primed for sexual health products alongside their GLP-1 prescriptions. The Novo Nordisk partnership announced by Hims & Hers in March 2026 positioned the company squarely at this intersection.

The overlap between the GLP-1 market (estimated at $50B+ annually and growing) and the sexual wellness market ($30B+ and growing) is a significant opportunity that has received almost no direct product development attention. The brands that move first to address GLP-1-specific sexual wellness needs — formulating lubricants marketed for GLP-1 dryness, or building telehealth journeys that address libido alongside weight management — are entering white space.

Sources

Update — 2026-04-18

Initial entry — story first created.